 Syndax Pharmaceuticals Inc NASDAQ: SNDX revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin mNPM1 or mixed-lineage leukemia rearranged MLLr relapsedrefractory acute leukemias. The data were featured at the American Society of Hematology ASH Annual Meeting. 